Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Reglan (metoclopramide) can cause movement-related side effects, including restlessness, muscle stiffness, tremor, involuntary facial or limb movements, and tardive dyskinesia, which may be permanent. Because this risk rises with longer use and higher cumulative doses, treatment is generally limited to 12 weeks or less, and the drug carries a boxed warning. Several factors influence individual risk, including age, kidney function, diabetes, and other medications, so see below to understand the important details before continuing or stopping therapy.
If you have noticed twitching, tongue or lip movements, inner restlessness, or stiffness while taking this medication, understanding whether your symptoms point to a drug reaction or something else can help you act quickly, since early recognition improves outcomes. Take a free, instant, online symptom check to clarify what may be happening and get guidance on your next steps.
Last reviewed for medical accuracy: 09/28/2026
Reglan (metoclopramide) is a medication often prescribed for heartburn, acid reflux, nausea and vomiting. While it can be effective, one of the most serious concerns is its potential to cause movement-related side effects. Understanding these risks—and why treatment courses are usually kept brief—helps you make informed decisions and discuss options with your doctor.
Because Reglan interferes with dopamine—a brain chemical that helps regulate movement—it can lead to a range of movement disorders. These side effects can occur at any time, but the risk increases with higher doses and longer use.
Reglan’s risk of movement disorders grows the longer you’re on it. To minimize this risk, guidelines recommend:
By following these principles, healthcare providers balance the benefits of symptom relief with the goal of preventing potentially irreversible side effects.
If you experience unusual movements, restlessness or muscle stiffness, it’s important to get evaluated. You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
free, online symptom check, using the doctor approved Ubie Symptom Checker
This tool can help you clarify your symptoms before speaking with a healthcare professional.
While many side effects improve after stopping Reglan, some can be life-threatening:
If you experience any of these, seek emergency medical care or call your local emergency number right away.
Open communication with your healthcare provider ensures you get the benefits of Reglan with the lowest risk:
Your health matters. If you notice any troubling movement changes or other side effects, don’t wait—talk to your doctor as soon as possible.
(References)
* Lal S. Pathophysiology and pharmacotherapy of spasmodic torticollis: a review. Can J Neurol Sci. 1979 Nov;6(4):427-35. doi: 10.1017/s0317167100023830. PMID: 94551.
* Price P, Debono A, Parkes JD, Marsden CD, Rosenthaler J. Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. Br J Clin Pharmacol. 1978 Oct;6(4):303-9. doi: 10.1111/j.1365-2125.1978.tb00856.x. PMID: 359016; PMCID: PMC1429466.
* Iakimovskiĭ AF. [Neuropharmacological activity of cerucal and haloperidol by intraperitoneal and intrastriatal administration in rats]. Biull Eksp Biol Med. 1991 Dec;112(12):602-4. PMID: 1777621.
* Batts KF, Munter DW. Metoclopramide toxicity in an infant. Pediatr Emerg Care. 1998 Feb;14(1):39-41. doi: 10.1097/00006565-199802000-00011. PMID: 9516631.
* Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull. 2002 Winter;36(1):82-93. PMID: 12397849.
* Adeleye JO, Akinyemi RO, Balogun WO, Onyegbutulem HO. Unusual presentation of thyrotoxicosis--a case report and review of literature. West Afr J Med. 2005 Jul-Sep;24(3):274-7. doi: 10.4314/wajm.v24i3.28215. PMID: 16276712.
* Kamata K, Takahashi E, Morioka N, Nakashima K, Iwade M, Ozaki M. [Metoclopramide Induced Acute Dystonia during Intravenous Patient-controlled Analgesia with Droperidol]. Masui. 2015 Oct;64(10):1076-9. PMID: 26742414.
* Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci. 2018 Jun 15;389:43-47. doi: 10.1016/j.jns.2018.02.006. Epub 2018 Feb 5. PMID: 29433808.
* Holland EL, Saneto RP, Knipper EK. Hypermetabolic Syndrome and Dyskinesia After Neurologic Surgery for Labrune Syndrome: A Case Report. A A Pract. 2020 May;14(7):e01212. doi: 10.1213/XAA.0000000000001212. PMID: 32371820.
* Khamis A, Dygulski S. Low-dose metoclopramide-induced dystonia in cannabis withdrawal syndrome manifesting as intractable nausea and vomiting. BMJ Case Rep. 2025 May 16;18(5):e264815. doi: 10.1136/bcr-2025-264815. Epub 2025 May 16. PMID: 40379294.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.